AdvertiseDonate
AboutRSSLas VegasNorth Las VegasHendersonRiversideAnaheimBakersfieldIrvineSanta Ana
November 18, 2026
Viral Report Now · 101 Convention Center Dr., Suite 900, Las Vegas, NV 89109

Hims & Hers introduces five peptide treatments amid ongoing scientific debate

The telehealth company launches new unapproved peptide formulations, acknowledging that more research is needed to determine their safety and efficacy.

By Lorenzo Marshall ·

Illustration for: Hims & Hers introduces five peptide treatments amid ongoing scientific debate
Illustration generated for this article, not a news photograph.

Hims & Hers Health announced on Wednesday that it will begin offering five peptide and longevity treatments compounded in the United States. These initial products under the company's Peptides+ platform are not currently approved by federal regulators. The launch comes as the company acknowledges that further learning is required regarding the optimal usage and effectiveness of these short chains of amino acids. This admission underscores the uncertainty that continues to surround the rapidly growing market for peptide therapies.

The new offerings follow a recent easing of federal restrictions on compounding certain unapproved peptides. These substances have seen a surge in popularity among fitness enthusiasts and those focused on longevity, who claim they aid in muscle growth, injury recovery, and anti-aging processes. Despite this enthusiasm, most of the products lack evidence from robust human clinical trials. Hims launched an early access list in late October, and a company spokesperson noted that more than 10,000 individuals signed up within just 15 days.

The initial lineup includes compounded formulations of sermorelin, which stimulates growth-hormone release, and glutathione, promoted for athletic recovery and anti-aging purposes. The company is also offering nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in cellular metabolism, along with vitamin B-12 and L-carnitine. While the FDA has approved prescription forms of vitamin B-12 and L-carnitine for specific medical deficiencies, the compounded versions offered by Hims are not formally approved for these broader wellness uses.

Hims stated that the products are legally authorized and formulated by pharmacies that are licensed, inspected by state boards, and adhere to rigorous quality standards. The company plans to expand its catalog over time to include other unapproved peptides such as BPC-157 and TB-500. Research on these additional compounds has primarily been conducted in animals rather than humans. Patients will begin with an assessment by a licensed provider to create a personalized treatment plan, with ongoing check-ins via the company's communication platform to monitor results.

Dr. Anant Vinjamoori, the company's chief medical officer, admitted that there is still uncertainty regarding the best practices for peptide use. He noted that the company lacks the extensive data typically available for established compounds. However, he emphasized that Hims views it as a responsibility to lead in this space given its resources. Patients with serious conditions such as cardiovascular, liver, or kidney disease are not currently candidates for these treatments.

Andrew Huberman, a neuroscientist and recent board member, described the compounds as real medical treatments rather than just a wellness trend. He highlighted the importance of trusted sourcing and physician oversight. However, health experts have raised concerns about the mainstream marketing of these unapproved substances through telehealth platforms. Joshua Kritzer, a chemistry professor at Tufts University, argued that without rigorous testing, users rely on anecdotal information, which is insufficient for prescribing a substance to the body.

Paul Knoepfler, a professor at UC Davis Health, pointed out that the lack of large clinical trials makes it difficult to establish proper dosing. He warned that injecting synthetic peptides could trigger immune responses if the body recognizes them as foreign. Knoepfler described the current landscape as loosey-goosey, noting that effective dosages and risk levels are not well defined. He recommended that patients maintain close contact with physicians who can consider their medical history and other medications.

The legal ability to sell these products stems from an October policy by the Health and Human Services Department. This policy states that the FDA will not enforce action against licensed pharmacies compounding six specific unapproved peptides while formal rules are reviewed. This shift reverses a 2023 decision that restricted such compounding due to safety concerns. HHS Secretary Robert F. Kennedy Jr. has supported broader access, calling himself a fan of the treatments and arguing that restrictions drove consumers to unsafe overseas products.

Scientific evidence for the efficacy of these peptides varies significantly. A 2026 systematic review found no eligible clinical trials proving that intravenous or intramuscular NAD+ improves anti-aging or energy endpoints in humans. While some evidence supports L-carnitine for modest weight loss, it is unclear if compounded injections work the same way. Vitamin B-12 injections are typically reserved for diagnosed deficiencies, which affect only 3.6% of U.S. adults. Glutathione evidence is also thin, with one study suggesting it is not very effective for skin lightening and loses efficacy over time. The FDA reported at least 30 adverse events linked to compounded IV glutathione, often from dietary supplement-grade ingredients not suitable for injectable drugs.

These existing studies and reports do not specifically address how Hims' exact formulations will perform. However, they highlight the current limits in data and the questions surrounding the safety and effectiveness of these treatments as they become more widely available through major telehealth platforms.

More News · National news · Report a business · Got a Story?

Get Viral Report Now in your inboxReporting on the stories people talk about. Free, a few times a week, unsubscribe any time.

Get Viral Report Now in your inboxReporting on the stories people talk about. Free, a few times a week, unsubscribe any time.